Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects
Authors:
- Raymond T ChungRCRaymond T Chung
- Scott R EvansSEScott R Evans
- Yijun YangYYYijun Yang
- Dickens TheodoreDTDickens Theodore
- Hernan ValdezHVHernan Valdez
- Rebecca ClarkRCRebecca Clark
- Cecilia ShikumaCSCecilia Shikuma
- Thomas NevinTNThomas Nevin
- Kenneth E ShermanKSKenneth E Sherman
- 1 September 2002
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (14) , 1915-1923
Abstract
The impact of highly active antiretroviral therapy (HAART) on hepatitis C virus (HCV) is unknown. We analysed changes in HCV RNA and the frequency of hepatotoxicity in co-infected patient enrolling in AIDS Clinical Trials Group trials, and determined whether HCV impairs successful immune reconstitution in these populations. In a prospective analysis of co-infected patients completing at least 16 weeks of HAART in four trials, and co-infected patients with available stored plasma from two other completed HAART trials, HCV RNA was measured at baseline and to week 48. A retrospective analysis of immune recovery in 40 HCV-RNA-positive and 129 HCV-RNA-negative patients from a single trial was performed. Prospective analysis: 60 patients completed at least 16 weeks of HAART. The mean HCV-RNA level increased 0.35 log10 IU/ml at week 16 and 0.43 log10 IU/ml at week 48. When stratified by baseline CD4 cell count, subjects’ HCV-RNA levels increased 0.43 and 0.59 log10 IU/ml at weeks 16 and 48 for entry CD4 cell counts < 350 cells/mm3, but only 0.26 and 0.1 log10 IU/ml at weeks 16 and 48 for entry CD4 cell counts > 350 cells/mm3. Severe alanine aminotransferase elevations occurred in only 3.3%. Retrospective analysis: HCV co-infection had no effect on the overall mean CD4 cell increase at weeks 16 or 48 compared with uninfected controls. In HCV-co-infected patients undergoing HAART, immune recovery is associated with a persistent increase in HCV RNA, especially with baseline CD4 cell counts < 350 cells/mm3. HCV co-infection did not antagonize the CD4 cell response to HAART.Keywords
This publication has 22 references indexed in Scilit:
- Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials GroupClinical Infectious Diseases, 2002
- Hepatitis C Virus Is Related to Progressive Liver Disease in Human Immunodeficiency Virus–Positive Hemophiliacs and Should Be Treated as an Opportunistic InfectionThe Journal of Infectious Diseases, 1999
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug TherapyNew England Journal of Medicine, 1998
- Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?AIDS, 1998
- Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis CThe Lancet, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- The Association between Hepatitis C Virus Genotype and Human Immunodeficiency Virus Disease Progression in a Cohort of Hemophilic MenThe Journal of Infectious Diseases, 1997
- Hepatitis C in human immunodeficiency virus-coinfected patients: Increased variability in the hypervariable envelope coding domainHepatology, 1996
- A longitudinal analysis of hepatitis C virus replication following liver transplantationGastroenterology, 1996